<DOC>
	<DOCNO>NCT02303431</DOCNO>
	<brief_summary>This first evaluation edoxaban pediatric subject . In Phase 1 study , single dose edoxaban give pediatric subject require anticoagulant therapy see body drug ( pharmacokinetics ) drug body ( pharmacodynamics ) , compare effect similar observe adult .</brief_summary>
	<brief_title>Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics ( PK/PD ) Study</brief_title>
	<detailed_description>Phase 1 , open-label , multiple-center study pediatric patient 0 &lt; 18 year age . Patients receive single dose edoxaban match either 30 mg ( low dose ) 60 mg ( high dose ) exposure adult . Exact dos select study basis PK model emerge data . If unanticipated exposure observe , target dos may modify best match expect exposure response relationship observe adult . Enrollment study start low dose , high age group ( adolescent ) continue low high dose age group high low age group . Enrollment next dose/age cohort begin 50 % subject complete previous dose/age cohort . Age cohorts dose group : ( 6 participant low high dose group , total 12 participant per age cohort ) - 12 &lt; 18 year age - 6 &lt; 12 year age - 2 &lt; 6 year age - 6 month &lt; 2 year age - 0 &lt; 6 month age</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Is pediatric subject require anticoagulant therapy Will abstain use nonsteroidal antiinflammatory drug ( ibuprofen ) , antiplatelet anticoagulant agent ( except aspirin ) 24 hour prior edoxaban dose last PK sample collect Will follow food concomitant medication restriction Any major clinically relevant unexplained bleed prior anticoagulant therapy History abnormal bleeding coagulation within last 6 month prior study drug administration Renal function glomerular filtration rate ( GFR ) less 50 % normal age size Malabsorption disorder ( e.g. , cystic fibrosis short bowel syndrome ) Hepatic disease associate coagulopathy lead clinically relevant bleeding risk , alanine transaminase ( ALT ) &gt; 5 time upper limit normal ( ULN ) total bilirubin &gt; 2 time ULN direct bilirubin &gt; 20 % total</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Pharmacokinetics ( PK )</keyword>
	<keyword>Pharmacodynamics ( PDy )</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>Safety</keyword>
</DOC>